SCHEMBL30848745

SCHEMBL30848745

COc1ccc(-c2cc(=O)c3c(OC)cccc3o2)cc1OC

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.75
ALDH1A1 P00352 7/20 0.74
KDM4E B2RXH2 5/20 0.74
CYP3A4 P08684 5/20 0.74
MAPT P10636 5/20 0.74
HSD17B10 Q99714 4/20 0.74
HPGD P15428 4/20 0.74
TP53 P04637 3/20 0.74
MEN1 O00255 4/20 0.73
KMT2A Q03164 4/20 0.73
CYP2D6 P10635 1/20 0.73
CYP2C9 P11712 1/20 0.73
CYP2C19 P33261 1/20 0.73
ABCB1 P08183 5/20 0.71
MAPK1 P28482 3/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
GLA P06280 1/20 0.71
THRB P10828 1/20 0.71
ABCG2 Q9UNQ0 3/20 0.69
MDM2 Q00987 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2481955 1.00 AR (0.75) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL3819575 0.88 CYP1B1 (0.75) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL10432745 0.88 CYP3A4 (0.66) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL9137273 0.86 AR (0.80) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL3825575 0.86 AR (0.80) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL7603117 0.86 AR (1.00) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL3820249 0.86 ALDH1A1 (0.74) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL1629391 0.85 ALDH1A1 (1.00) ARALDH1A1KDM4ECYP3A4MAPT
Tetramethylluteolin SCHEMBL29572571 0.84 ABCB1 (0.80) ALDH1A1KDM4ECYP3A4MAPTHSD17B10
SCHEMBL4649207 0.84 KDM4E (1.00) ARALDH1A1KDM4ECYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250082602-A1 OPHTHALMIC COMPOSITION CONTAINING RECOFLAVONE FOR THE TREATMENT OF DRY EYE DISEASE GL PHARMTECH CORP. (KR) 2025-03-13 US disclosed
CN-117794515-A Eye drop composition comprising releavance flavone for treating dry eye syndrome and method for preparing the same 格里医药科技公司 2024-03-29 CN disclosed
CN-117794514-A Eye drop composition comprising a releaf flavonoid for treating dry eye 格里医药科技公司 2024-03-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250082602-A1 OPHTHALMIC COMPOSITION CONTAINING RECOFLAVONE FOR THE TREATMENT OF DRY EYE DISEASE NR1H4, NR1H2, NR1H3 AR 3560/4885ALDH1A1 3395/4885KDM4E 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.